Using targeted mRNA therapies to treat acute respiratory distress syndrome (ARDS)
Targeted mRNA therapies treating ARDS
This study is exploring a new treatment for people with acute respiratory distress syndrome (ARDS) by using tiny particles to deliver special messages to help heal the cells in their lungs, especially for those who have been seriously affected by influenza or COVID-19.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10891734 on NIH RePORTER |
What this research studies
This research focuses on developing innovative therapies using targeted mRNA delivered through specially designed nanoparticles to treat acute respiratory distress syndrome (ARDS). The approach aims to enhance the health of endothelial cells by delivering specific mRNA that can help restore their function. The research is being conducted at the University of Chicago, where a team of expert scientists is guiding the project. Patients with ARDS, particularly those affected by severe influenza or COVID-19, may benefit from this novel treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from acute respiratory distress syndrome, especially those with severe cases related to viral infections like COVID-19.
Not a fit: Patients with chronic respiratory conditions or those not experiencing acute respiratory distress may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for ARDS, potentially reducing mortality rates associated with severe respiratory conditions.
How similar studies have performed: Previous research has shown promise in using targeted nanoparticle delivery systems for mRNA therapies, indicating potential success for this novel approach.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Zhou, Zhengjie — University of Chicago
- Study coordinator: Zhou, Zhengjie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.